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Background: Currently, 13-cis-retinoic acid (13-cis-RA) is the most effective therapy for acne. Isotretinoin, a
ﬁrst-generation synthetic 13-cis-RA compound, is associated with numerous adverse effects. To investigate
the cardiac effects of 13-cis-RA, acne patients receiving 13-cis-RA were studied.
Methods: Twenty male patients with acne were enrolled in the study. Patients were treated with a dose of
0.5 mg/kg/d of isotretinoin. All participants were assessed prior to treatment and after 10 weeks of therapy
with Doppler-echocardiogram.
Results: Patients showed reductions in right atrium vertical diameter, left atrium longitudinal diameter, left
atrium volume and left ventricular diastolic diameter over the course of treatment. Signiﬁcant increases in
interventricular septum diastolic thickness, posterior wall diastolic thickness, relative wall relative thickness
and left ventricle (LV) mass were observed. The LV mass index showed an increase in ventricular mass and a
decrease in the cavity size. Examining LV systolic function, a decrease was observed for the cardiac index.
Conclusion: In this study, 10 weeks of 13-cis-RA therapy at a dose of 0.5 mg/kg/d was found to promote
concentric-type heart remodeling due to the occurrence of two associated events: heart hypertrophy and
hypovolemia.
© 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Retinoic acid (RA) is the bioactive metabolite of vitamin A. It acts
through nuclear retinoid receptors (RAR and RXR), alters protein
synthesis in the heart and regulates embryonic development, tissue
homeostasis and cellular differentiation and proliferation [1]. The
effects of RA during adulthood are still poorly understood. Experi-
mentally, it has been shown that all-trans-RA inhibits hypertrophy
and ﬁbrosis in spontaneously hypertensive rats [2], after myocardial
infarction [3] and in aortic-banded rats [4]. In rats with no
cardiovascular injury it was observed: 1) that a physiological dose
of all-trans-RA caused cardiac remodeling with left ventricular
hypertrophy, normal interstitial collagen and maintenance of cardiac
geometry [5], and 2) that a deﬁciency vitamin A diet promoted a
ventricular remodeling [6].
Some isomers of RA, including all-trans-RA, 9-cis-RA and 13-cis-RA
are important to the heart with differing biological activities.
All-trans-RA is a ligand for RARs, whereas 9-cis-RA is a high-afﬁnity
ligand for both the RXRs and the RARs [7–9]. Because 13-cis-RA has
little or no binding afﬁnity for RARs and RXRs [10,11], the effects ofedica, Faculdade de Medicina
8618-000, Brazil. Tel.: +55 14
r the Elsevier OA license.13-cis-RA are thought to occur through the isomerization of 13-cis-RA
to all-trans-RA and/or to 9-cis-RA [12].
For more than 25 years, 13-cis-RA has been used as an acne
treatment [13], and it is the most effective systemic treatment option
for severe acne. Isotretinoin is a ﬁrst-generation synthetic retinoid
that affects the skin and mucous membranes, the central nervous
system, the gastrointestinal tract, and the musculoskeletal system
[14].
Selcoki et al. used 24-h Holter electrocardiography monitoring for
six months in isotretinoin therapy patients and did not ﬁnd
arrhythmic effects [15]. However, more studies are needed to obtain
more precise results about the adverse cardiac effects of isotretinoin.
Therefore, this study aimed to use Doppler-echocardiography to
observe cardiac alterations in normal youth and adult subjects with
acne vulgaris undergoing isotretinoin treatment.
2. Patients and methods
2.1. Subjects and treatment
This prospective study included twenty consecutive male adolescents and young
adults aged 13 to 24 years (mean age of 17.3±2.6 years). Subjects were candidates to
use 13-cis-RA (isotretinoin) at a single daily dose of 0.5 mg/kg. Subjects were followed
at the Dermatology Outpatient Unit of the Botucatu School of Medicine University
Hospital (FMB, UNESP). Exclusion criteria included being female, having diabetes
mellitus, obesity, low weight, alcoholism, renal failure, previous hepatopathies,
cardiopathies, dyslipidemias or inﬂammatory diseases of any etiology except acne
Table 1
Data for cardiac morphometric variables.
Variables IM FM p value
LA (cm) 3.3±0.4a 3.3±0.3 0.389
LA1 (cm) 4.5±0.6 4.2±0.7 0.033
LA2 (cm) 3.9±0.4 3.9±0.5 0.600
LA volume (ml) 31.3±7.9 28.3±9.1 0.023
RA1 (cm) 4.3±0.5 4.1±0.5 0.019
RA2 (cm) 4.0±0.5 3.7±0.9 0.137
LVDD (cm) 5.0±0.4 4.9±0.4 0.019
LVSD (cm) 3.10 (2.88–3.30)b 3.10 (2.80–3.35) 0.761
RVAd (cm2) 20.22±4.19 22.12±5.88 0.149
RVAs (cm2) 11.42±3.20 12.27±3.01 0.247
IVSDT (cm) 0.70 (0.70–0.80) 0.85 (0.80–0.90) 0.001
PWT (cm) 0.73 (0.70–0.80) 0.81 (0.80–0.90) 0.007
RWT 0.29±0.03 0.34±0.05 0.002
LVM (g) 124.2±25.5 143±36.7 0.007
LVMI (g/m2) 68.8±11.1 78.6±16.7 0.033
IM and FM: Initial and ﬁnal moments; LA: Left atrium diameter; LA1 and LA2: Left
atrium longitudinal and cross-sectional diameters; RA1 and RA2: Right atrium vertical
and cross-sectional diameters, respectively; LVDD and LVSD: Left ventricular diastolic
and systolic diameters, respectively; RVAd and RVAs: Diastolic and systolic right
ventricle areas, respectively; IVSDT: Interventricular septum diastolic thickness; PWT:
Posterior wall diastolic thickness; RWT: Relative wall relative thickness; LVM: Left
ventricle mass; LVMI: Left ventricle mass index.
Bold values indicates statistical signiﬁcance (b0.05).
a Means and standard deviations.
b Medians and quartile 1 and quartile 3.
Table 2
Data for left ventricle systolic and diastolic function variables.
Variables IM FM p value
EF 0.59±0.06a 0.62±0.05 0.127
% ΔD 38.2±6.2 36.4±4.7 0.116
SV (ml) 67.7±15.0 63.7±15.9 0.084
CO (L/min) 4.50±1.18 4.08±0.99 0.061
CI (L/min/m2) 2.50±0.60 2.24±0.43 0.044
E (cm/s) 91.8±15.1 82.4±16.4 0.004
A (cm/s) 47±9.2 39.8±8.9 0.006
E/A ratio 2.0±0.5 2.2±0.8 0.289
DT (ms) 187±53.7 178±53.1 0.455
IRT (ms) 77.1±17.7 77.4±12.7 0.932
E′ (cm/s) 14.0±3.6 15.2±4.5 0.196
A′ (cm/s) 7.4±2.4 9.1±3.1 0.016
E/E′ 6.9±1.7 5.7±1.3 0.004
IM and FM: Initial and ﬁnal moments; EF: Ejection fraction; %ΔD: Left ventricular
fractional shortening; SV: Stroke volume; CO: Cardiac output; CI: Cardiac index; E: Early
peak transmitral ﬂow velocity; A: Late peak transmitral ﬂow velocity; DT: E-wave
deceleration time; IRT: Left ventricle isovolumetric relaxation time; E′: Early peak
velocity of mitral annular motion; A′: Late peak velocity of mitral annular motion.
Bold values indicates statistical signiﬁcance (b0.05).
a Means and standard deviations.
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subjects provided informed consent, and the School of Medicine's Research Ethics
Committee approved the study.
Patients were evaluated prior to the beginning of treatment (initial moment—IM)
and after 10 weeks of treatment (ﬁnal moment—FM). Clinical evaluation, Doppler-
echocardiogram and measures of serum total protein and fractions (TP and albumin),
C-reactive protein (CRP) and alpha-glycoprotein were performed on the same day.
2.2. Clinical evaluation
The same physician examined all individuals. The following parameters were
recorded: weight, height, arterial blood pressure and cardiac frequency. Clinical signs
and symptoms of medication toxicity were also investigated.
2.3. Dietary intake
The food intake evaluation included a 24-h dietary recall and a food frequency
questionnaire (FFQ) [16]. The FFQ consisted of a list of 62 food types, preparations and
drinks. The home measurements described by the patients were converted into grams
or milliliters, according to Pinheiro et al.[17]. The data were changed into retinol
equivalents, numbers of calories and grams of proteins, lipids and carbohydrates.
2.4. Doppler-echocardiographic evaluation
All exams were performed by the same cardiologist (BBM) following standard
procedures for image recording and measurements [18]. Ultrasounds were performed
with an HDI® 5000 SONOCT (Philips, Andover, MA). Left ventricle (LV) mass was
estimated from linear dimensions as: LV mass (g)=0.8×{1.04 [(LVDD+PWT+
IVSDT)³−(LVDD)³]}+0.6, where LVDD, PWT and IVSDT represent the diastolic LV
diameter, posterior wall thickness and septal wall thickness, respectively. LV mass was
normalized for body surface area (LVMI, g/m²). Relative wall thickness (RWT) was
calculated as 2PWT/LVDD. LV systolic function was assessed by ejection fraction (EF)
using the modiﬁed Simpson's rule and Doppler-derived stroke volume (SV), cardiac
output (CO) and indexed CO (CI). Diastolic function was evaluated using pulsed
Doppler recordings of mitral inﬂow velocities E and A waves (cm/s), deceleration time
(DT, ms), isovolumic relaxation time (IRVT, ms), and also tissue Doppler-derived septal
diastolic mitral annular motion (E’, cm/s) and left atrial volume indexed to body surface
area (LAVI, ml/m²). The dimensions of the left atriumwere also evaluated bymeasuring
the maximum diameter (LA, cm) in the parasternal view, the short axis in the
mono-dimensional image and longitudinal (LAl) and cross-sectional (LA2) diameters
(cm) obtained in the two-dimensional four-chamber apical view. Right ventricular
chamber dimensions were evaluated using the same view by measuring the
longitudinal and cross-sectional diameters of the right atrium (RA1 and RA2,
respectively) and systolic and diastolic right ventricular areas. Doppler-derived lateral
tricuspid annular motion was recorded for right ventricular function analysis.
2.5. Biochemical evaluation
Albumin, C-reactive protein (CRP) and alpha-glycoprotein were measured from
serum. Testing was performed using dry chemistry methodology on a Vitros 950
device (Johnson & Johnson, Rochester, NY).
2.6. Statistical methods
Differences between values at the initial and ﬁnal moments were compared using
the paired sample t-test or the Wilcoxon signed-rank test. SigmaStat for Windows v3.5
(SPSS Inc, Chicago, IL) was used. All values are expressed as mean±SD, or median
(quartile 1–quartile 3). The statistically signiﬁcant level was set at 0.05 for all
calculations.
3. Results
There were no signiﬁcant differences over time in relation to
weight, height, body mass index, food ingestion, systolic arterial
pressure, diastolic arterial pressure or heart rate (data not shown).
There was no difference in the serum albumin [IM=4.70 (4.52–4.87)
g/dl, FM=4.70 (4.60–5.00) g/dl; p=0.818], in the CRP [IM=0.10
(0.00–0.70) mg/dl, FM=0.20 (0.07–0.40) mg/dl; p=0.426] or in the
alpha-glycoprotein [IM=92.5±27.9 mg/dl, FM=70.0±20.4 mg/dl;
p=0.220].
3.1. Doppler-echocardiographic evaluation
Over the treatment period, there was a reduction in RA1, LA1
diameter, LA volume and LVDD. Signiﬁcant increases in IVSDT, PWT,RWT, LVM and LVMI were observed, with increases in ventricular
mass and decreases in cavity size, as shown in Table 1.
Table 2 shows the echocardiographic variables that evaluate LV
systolic and diastolic function. A decrease was observed between the
initial and ﬁnal moments in the cardiac index for LV systolic
functioning.
There was a decrease in the left ventricle fast ﬁlling maximum
velocity, left ventricle late ﬁllingmaximumvelocity, the ratio between
peaks of ﬂow velocity and mitral annulus movement at the beginning
of diastole and LA variation fraction. The peak of the displacement
velocity for the septal portion of the mitral annulus increased during
atrial contraction (Table 2).
4. Discussion
Cardiac remodeling is deﬁned as an alteration in protein synthesis,
which results in molecular, cellular and interstitial cardiac changes.
Such alterations can clinically manifest as changes in cardiac volume,
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ﬁndings in our study were an increase in ventricular mass and a
decrease in the size of the chambers. Together, these results lead us to
assume that the patients developed cardiac hypertrophy, although the
absolute values did not surpass the upper limits of normality for any of
the measured variables.
Several mechanisms could explain this ﬁnding of myocardial
growth, including nutritional status improvement, body growth,
physical exercise, pressure overload, inﬂammation status and retinoid
acid action.
4.1. Nutritional status
Acne is a disease characterized by dermal inﬂammation, and
inﬂammation is a possible cause of protein-energy malnutrition
(PEM). In the present study, the subjects showed normal weight and
height for their age [21]. These observations allowed us to exclude
nutritional status as a determinant for myocardial growth.
4.2. Growth
When analyzing weight and height values, it was also important to
note that the initial and ﬁnal moment measurements were not
signiﬁcantly different. This lack of change led us to disfavor physical
development as a variable that could be associated with cardiac
structural alterations.
4.3. Physical exercise
Physical exercise could be associated with cardiac enlargement,
but was ruled out by the exclusion criteria.
4.4. Pressure overload
The ventricular remodeling process is inﬂuenced by various
stimuli, including mechanical factors like hemodynamic pressure
overload [22].
At the time the study began, our patients were normotensive, with
a mean SAP value of 112 mm Hg and a median DAP of 70 mm Hg.
None of them showed arterial pressure values that would indicate
systemic arterial hypertension, according to the V Brazilian Guidelines
for Arterial Hypertension (2006) [23]. Even so, signiﬁcant variations
within the normal limits could justify a gain in myocardial mass
during the protocol period. However, subjects maintained constant
systolic and diastolic arterial pressure values without signiﬁcant
variations between our ﬁrst and last evaluations of them, which led us
to discard such variables as the cause of myocardial mass increase.
Also, Karadag et al.did not show an increase in blood pressure in
patients receiving isotretinoin during a period of 3 months [24].
4.5. Inﬂammation
Acne vulgaris is a disease that affects pilosebaceous follicles, and it
is characterized by sebaceous hyperproduction, follicular hyperker-
atinization, bacterial colonization and periglandular dermal inﬂam-
mation [25]. Severe acne can also cause pain, fever, arthralgia and
anorexia. It can also cause a humoral inﬂammatory response
mediated by keratinocytes to occur, interleukin 1 (IL-1) as well as
tumor necrosis factor (TNF-α) to be produced and reactive oxygen
species to form [25]. Therefore, patients may face cutaneous and
systemic inﬂammatory processes.
In the present study, CRPwas used as an inﬂammationmarker. Our
patients did not show high levels of this marker prior to treatment
with 13-cis-RA, and no change was observed between the two
evaluations. This was also true for the acid alpha-glycoprotein,
another inﬂammation marker that was within normal values at thebeginning of our study and did not signiﬁcantly change over the
course of our study. Using routine analytical methods, the CRP
detection limit is 0.5 mg/dl, but using ultra-sensitive methods, it is
possible to detect CRP levels as low as 0.08 mg/dl. Recent studies have
shown that even slightly increased CRP is a cardiovascular risk factor.
We did not use the ultra-sensitive method in our study; hence, we
may have failed to detect atherosclerotic or similar inﬂammatory
processes, in which CRP levels above 0.3 mg/dl are associated with
higher cardiovascular risk.
The relationship between inﬂammation and cardiac hypertrophy
is well established in the literature. In type 2 diabetes mellitus,
Palmieri et al. showed that the higher the CRP, the greater the risk of
hypertrophy in the left ventricle [26]. This was also observed in a
cross-sectional study [27]. Additionally, experimental studies have
shown that inﬂammatory cytokines, such as TNF-α and interleu-
kin-1b among others, can contribute to the development and
progression of cardiac failure, since they promote cardiac hypertrophy
by activating cellular matrix metalloproteinases, causing contractile
dysfunction and inducing apoptosis [28]. In the present study, no
alterations in inﬂammatory activity markers were observed. Addi-
tionally, since RA attenuates inﬂammation, treatment would tend to
reduce ventricular mass; however, cardiac hypertrophy was found.4.6. Concentric remodeling or “pseudohypertrophy”
In amodel of bleeding hypovolemia in pigs, Di Segni et al. [29] used
echocardiography to observe an increase in the left ventricle posterior
wall and interventricular septum, a decrease in the left ventricle
diastolic and systolic diameter, an increase in the left ventricular wall
relative thickness and maintenance of left ventricular mass. The
authors called such alterations “pseudohypertrophy” [29]. Another
study involving hypovolemia and echocardiographic measurements
was conducted by Boussuges et al. [30] on healthy volunteers who
were submitted to hyperbaric exposure and hyperoxia through the
performance of a fasting physical activity session. In addition to a
reduction in the heart's left chambers, a decrease in ventricular
systolic function indexes (percentage of ventricular diameter short-
ening and cardiac output) was observed while heart rate was
maintained [30].
Some of these previously published data are consistent with the
present study, i.e. increased left ventricle wall thickness, chambers
reduction and decreased heart rate. Taken together, these would
suggest a hypovolemic state. However, in the studies by Di Segni et al.
[29] and Boussuges et al. [30], LVM remained unchanged by the
proportionality between the increase in the left ventricle walls (IVSDT
and PWT) and cavity reduction. However, in our study, LVM and LVMI
increased.
RA has effects that can explain our ﬁndings of cardiac hypertrophy
and cavity reduction: direct action on the heart and peripheral action
on the renin–angiotensin–aldosterone system.
Our ﬁnding of LV mass increase can be explained by the direct
action of vitamin A on the heart. We have previously shown that
Wistar rats receiving a standard diet plus a low dose of RA for
90 days show an increased LV mass [5]. Also, light microscopy
revealed that myocyte sectional area was increased without collagen
fraction volume variation, indicating hypertrophy without interstitial
ﬁbrosis.
This cardiac hypertrophy could be explained by an effect of
vitamin A on growth and cellular differentiation, as well as by the fact
that RAR and RXR receptors act as DNA transcription factors, similar to
receptors for cortisol, vitamin D and thyroidal hormone [31].
Additionally, the activation of the RXR-PPARγ complex has been
described as a cause of cardiac hypertrophy. RXRβ activation by the
supply of in normotensive rats for 90 days resulted in a 10% increase
in left ventricular mass [32].
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important regulator for cardiovascular and renal structure and
function, in addition to providing salt and water balance [33].
Treatment with RA increases expression of the angiotensin-
converting enzyme 2 (ACE2) at both the mRNA and protein levels,
resulting in blood pressure reduction and attenuation of myocardial
damage [34]. Thus, the vasodilating action of ACE2 and its participa-
tion in the salt and water balance could lead to hypovolemia and
reduced chambers and blood ﬂow velocities. All-trans-RA can inhibit
the renin–angiotensin–aldosterone system under experimental con-
ditions [4]. Therefore, our patients may have been under conditions of
lower salt andwater retention during the study period.We observed a
reduction in mitral transvalvular blood ﬂow velocity, thus supporting
this hypothesis. In individuals without cardiovascular disease, these
indicators are closely associated with the circulating volume. That is,
in situations of smaller venous return, there would be a reduction in
diastolic ﬂow velocity through the atrioventricular valves. The
observation of a lower cardiac index at the ﬁnal time point of our
study reinforces this hypothesis.
A potential limitation of this study is that it is not a randomized
clinical trial and no control groups were included.
We conclude that a ten week 13-cis-RA treatment promotes
concentric-type heart remodeling due to the occurrence of two
associated events: heart hypertrophy and hypovolemia.
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